April 16, 2025

Is Primary Care Becoming Pay-to-Play?

“It’s a way to practice self-preservation in this field that is punishing patients and doctors alike” — one internist explains why some rural physicians are opting for concierge care despite the access trade-offs.

KFF Health News

April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant

April 11, 2025

FDA Clears Longest Lasting CGM

Dexcom G7 15 Day receives FDA clearance, offering adults with diabetes the longest lasting and most accurate continuous glucose monitoring system to date.

Conexiant

April 10, 2025

FDA to Pilot Animal-Free Models

"This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use."

Reuters

April 07, 2025

HHS FOIA Staff Cuts Slow Data

Thousands of pending FOIA requests are likely to be affected.

KFF Health News

April 04, 2025

Gram-Negative Infection: 7 vs 14 Days of Antibiotics

Mortality occurred in 12.8% of the patients in the 7-day group compared with 13.7% of those in the 14-day group.

Conexiant

April 03, 2025

New Option for IgA Nephropathy Management

The FDA has granted accelerated approval to Vanrafia (atrasentan) for reducing proteinuria in adults with primary immunoglobulin A nephropathy who are at risk of rapid disease progression.

Conexiant

April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant